Normative modelling reveals distinct neural correlates of olfactory and cognitive impairments in patients with Parkinson's disease: A retrospective observational study
Background: Hyposmia is predictive of dementia but typically unaware in patients with Parkinson ’s disease (PD). The olfactory and cognitive impairments can be independent processes, possibly due to varied neuropathological changes and confounded by the presence of olfactory anosognosia (OA). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: R. Ye, F. Xing, J. Feng, J. Liu, J. Sun, T. Liu, R. Ma, K. Wang, P. Hu Source Type: research
Parkinson ’s Disease with Hyposmia and Dysautonomia: Does It Represent a Distinct Subtype?
Background: Olfactory dysfunction or dysautonomia is one of PD's earliest prodromal non-motor symptoms. We aimed to investigate whether PD patients with dysautonomia and hyposmia at the de novo stage present different prognoses regarding PD dementia (PDD) conversion, motor complication development, and change in levodopa-equivalent doses (LED). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: S.H. Yoon, D.H. You, H. Na, S. Kang, K. Baik, M. Park, C.H. Lyoo, Y.H. Sohn, P.H. Lee Source Type: research
Exploring the Role of Genetic Mutations and Clinical Features in the Conversion to α-Synucleinopathies
This study aims to evaluate the influence of genetic mutations and clinical symptoms on the risk of conversion to α-synucleinopathies. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: J. Qin, M. Zhang Source Type: research
Differences in Dopamine Transporter Loss Pattern by DaTscan among patients with Parkinson's disease, Dementia with Lewy bodies and Parkinson's disease with dementia
Background: 123-I FP-CIT SPECT (DaTscan) is used to diagnose Parkinson's syndrome, which is determined by ROI count and visual morphology. However, differential diagnosis may be difficult in cases where DaTscan accumulation is significantly reduced compared to clinical symptoms. The aim of this study is to investigate the Differences in Dopamine Transporter Loss Pattern by DaTscan among Parkinson's disease (PD), Dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: H. Senoo, T. Tokashiki, Y. Ohya, A. Nagayama Source Type: research
MAPT c.1999-1G > A Mutation presenting as Dysexecutive variant AD with CBS phenotype
Background: Cortico-basal syndrome- Alzheimer ’s disease (CBS-AD) phenotype can be differentiated clinically from Cortico-basal syndrome-Cortico-basal disease (CBS-CBD) type by longer duration of disease, dressing apraxia, memory loss, low mini-mental score at presentation, visuospatial difficulties and absence of limb rigidity. In patients w ith MAPT mutation, the most common clinical presentation is a classic frontotemporal dementia with parkinsonism linked to chromosome 17. Here we are describing a genetically proven MAPT gene mutation presenting in a relatively young onset as a dysexecutive variant AD with CBS phenot...
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: F. Mustafa, S. Sha, A. Das, D. Vibha, R. Kumar Singh, A. Elavarasi, J. Parihar, M. Tripathi Source Type: research
Parkinson ’s Disease with Hyposmia and Dysautonomia: Does It Represent a Distinct Subtype?
Background: Olfactory dysfunction or dysautonomia is one of PD's earliest prodromal non-motor symptoms. We aimed to investigate whether PD patients with dysautonomia and hyposmia at the de novo stage present different prognoses regarding PD dementia (PDD) conversion, motor complication development, and change in levodopa-equivalent doses (LED). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: S.H. Yoon, D.H. You, H. Na, S. Kang, K. Baik, M. Park, C.H. Lyoo, Y.H. Sohn, P.H. Lee Source Type: research
Exploring the Role of Genetic Mutations and Clinical Features in the Conversion to α-Synucleinopathies
This study aims to evaluate the influence of genetic mutations and clinical symptoms on the risk of conversion to α-synucleinopathies. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: J. Qin, M. Zhang Source Type: research
Anterior Attentional System Functioning in Patients with Parkinson ’s Disease Across Various Cognitive Statutes
This study aimed to assess the Anterior Attentional System efficiency in PD patients across various cognitive statutes: normal cognition (NC), mild cognitive impairment (MCI), and mild dementia (PDD). (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: P. Goli ńska, A. Sawicki, Ł. Bieleninik, M. Schinwelski, M. Bidzan Source Type: research
EEG biosignatures are sensitive and specific markers that distinctively characterize Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease
Background: Parkinson ’s Disease (PD) and Lewy Body Dementia (LBD) patients exhibit a range of motor, psychiatric, and cognitive symptoms associated with different stages of disease progression. There is a need for accurate, inexpensive biomarkers for early detection of the underlying pathology and to assess treatment efficacy. EEG biosignatures provide objective quantification of neurodegenerative disease and differentiate between PD, LBD and Alzheimer’s Dementia (AD) to map the trajectory of neurodegeneration and evaluate efficacy of novel disease-modifying treatments. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: C. Berka, A. Meghdadi, A. Verma, E. St. Louis, B. Boeve, C. Henchcliffe, D. Mozley Source Type: research
Pimavanserin for Psychosis in Parkinson ’s Disease Dementia: Subgroup Analysis of the HARMONY Trial
Background: Pimavanserin is FDA-approved to treat Parkinson ’s disease (PD) psychosis. We analyzed the effect of pimavanserin on psychosis in the PD dementia (PDD) subgroup from the phase 3 HARMONY trial. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: D. Weintraub, A.J. Espay, V.D. Sharma, P.N. Tariot, V. Abler, S. Pathak, S. Stankovic Source Type: research
The Association of Radiological Features to Predominant Cognitive Clinical Syndromes of Lewy Body Dementia
This study aims to clarify the relationship between the mentioned scales and the affected predominant neurocognitive area. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: O. Uyanik, M. Turkkol, F. Yadi, O. Totuk, S. Demir, S. Sahin Source Type: research
Evaluation of autonomic, imaging and genetic biomarkers for dementia in Parkinson ’s disease: A cohort description
Background: Among the wide spectrum of non-motor symptoms, Cognitive Impairment (CI) is a major feature of PD, and its diagnosis is often complex, as no reliable diagnostic biomarkers have been described yet. Mild cognitive dysfunction may present since the early stages, while dementia will occur in over 80% of patients after 20 years of disease, severely affecting the quality of life. Detection of early predictors of CI could help to stratify patients and set appropriate early interventions. We aimed to extensively characterize an early non-demented PD (NDPD) cohort to be studied prospectively, in order to identify potent...
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: P. Polverino, T. De Santis, A. Cocco, S. Lalli, E. Perdixi, A. Albanese Source Type: research
Experimental laboratory models as tools for understanding modifiable dementia risk
Alzheimers Dement. 2024 Apr 30. doi: 10.1002/alz.13834. Online ahead of print.ABSTRACTExperimental laboratory research has an important role to play in dementia prevention. Mechanisms underlying modifiable risk factors for dementia are promising targets for dementia prevention but are difficult to investigate in human populations due to technological constraints and confounds. Therefore, controlled laboratory experiments in models such as transgenic rodents, invertebrates and in vitro cultured cells are increasingly used to investigate dementia risk factors and test strategies which target them to prevent dementia. This re...
Source: The Journal of Alzheimers Association - April 30, 2024 Category: Psychiatry Authors: Duncan Sinclair Alison J Canty Jenna M Ziebell Adele Woodhouse Jessica M Collins Sharn Perry Eddy Roccati Maneesh Kuruvilla Jacqueline Leung Rachel Atkinson James C Vickers Anthony L Cook Anna E King Source Type: research
Mechanical ventilation in older adults with dementia: opportunities to promote goal-concordant care
CONCLUSION: Future efforts to promote goal-concordant care surrounding mechanical ventilation use for people living with dementia should involve identifying barriers to goal-concordant care in pre-hospital settings, assessing the timeliness of in-hospital GOCD, and developing strategies for in-the-moment crisis communication across settings.PMID:38685288 | DOI:10.1016/j.jpainsymman.2024.04.021 (Source: Pain Physician)
Source: Pain Physician - April 30, 2024 Category: Anesthesiology Authors: Lauren R Pollack Jamie T Nomitch Lois Downey Sudiptho R Paul May J Reed Alison M Uyeda Whitney A Kiker Danae G Dotolo Elizabeth Dzeng Robert Y Lee Ruth A Engelberg Erin K Kross Source Type: research
Frontotemporal dementia: from genetics to therapeutic approaches
Expert Opin Investig Drugs. 2024 Apr 30. doi: 10.1080/13543784.2024.2349286. Online ahead of print.ABSTRACTINTRODUCTION: Frontotemporal dementia (FTD) includes a group of neurodegenerative diseases characterized clinically by behavioral disturbances and by neurodegeneration of brain anterior temporal and frontal lobes, leading to atrophy. Apart from symptomatic treatments, there is, at present, no disease-modifying cure for FTD.AREAS COVERED: Three main mutations are known as causes of familial FTD, and large consortia have studied carriers of mutations, also in preclinical Phases. As genetic cases are the only ones in whi...
Source: Expert Opinion on Investigational Drugs - April 30, 2024 Category: Drugs & Pharmacology Authors: Francesca R Buccellato Marianna D'Anca Gianluca Martino Tartaglia Massimo Del Fabbro Daniela Galimberti Source Type: research
